ONCOLOGY FORUM QUESTION

Article

Rhetoric aside, initiatives such as comparative effectiveness and ACOs are designed to cut the costs of healthcare. Is there a way to effectively cut the cost of cancer care and maintain quality?

Rhetoric aside, initiatives such as comparative effectiveness and ACOs are designed to cut the costs of healthcare. Is there a way to effectively cut the cost of cancer care and maintain quality?

ONCOLOGY ed board member Donald Abrams, MD, weighs in…

Having worked in a relatively resource poor county hospital setting as an oncologist for nearly 30 years now, I appreciate that we have made incredible technologic advances in diagnosis and treatment of cancer patients. But I do need to wonder how many PET/CT scans I really need to order and how much longer my patients will survive if I test every tumor for markers and mutations up front.

Personally, I feel that the best way to cut the cost of cancer care would be if we paid more attention to cancer risk reduction through modifiable lifestyle changes.

The Standard American Diet is cancer fodder and most of my colleagues are totally unconscious or incredulous about the role of nutrition and physical activity in cancer. Oncologists should assume a lead role in promoting wellness and risk reduction as a way to cut cancer care costs up front so that we can continue to provide quality care to those patients who will still require it.

Donald I. Abrams, MD
Chief, Hematology-Oncology
San Francisco General Hospital
Integrative Oncology
UCSF Osher Center for Integrative Medicine
Professor of Clinical Medicine
University of California San Francisco
President, Society for Integrative Oncology
 

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Related Content